Inventor
LEVITSKY HYAM I
US13 patents
⚠️ This page may combine multiple inventors who share the name “LEVITSKY HYAM I”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV JOHNS HOPKINS MED
9 patentsUS6464973B1Oct 15, 2002
Universal GM-CSF expressing bystander human K562 cell line
UNIV JOHNS HOPKINS MED96 citations95
US6350445B1Feb 26, 2002
Method of treating cancer with a tumor cell line having modified cytokine expression
UNIV JOHNS HOPKINS MED78 citations95
US6033674AMar 7, 2000
Method of treating cancer with a tumor cell line having modified cytokine expression
UNIV JOHNS HOPKINS MED83 citations95
US5985290ANov 16, 1999
Purified pancreatic tumor cell lines and related compositions and method
UNIV JOHNS HOPKINS MED69 citations95
US8012469B2Sep 6, 2011
Universal GM-CSF expressing bystander human K562 cell line
UNIV JOHNS HOPKINS MED29 citations90
US8383096B2Feb 26, 2013
Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
UNIV JOHNS HOPKINS MED5 citations81
US7390483B2Jun 24, 2008
Universal GM-CSF expressing bystander human K562 cell line
UNIV JOHNS HOPKINS MED9 citations81
US7740871B2Jun 22, 2010
Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
UNIV JOHNS HOPKINS MED6 citations71
US6087174AJul 11, 2000
Growth medium for primary pancreatic tumor cell culture
UNIV JOHNS HOPKINS MED1 citations51
JUNO THERAPEUTICS INC
4 patentsUS10738278B2Aug 11, 2020
Engineered cells for adoptive cell therapy
JUNO THERAPEUTICS INC8 citations82
US10786533B2Sep 29, 2020
Engineered cells for adoptive cell therapy
JUNO THERAPEUTICS INC4 citations69
US11793833B2Oct 24, 2023
Engineered B cells and related compositions and methods
JUNO THERAPEUTICS INC0 citations62
US11896615B2Feb 13, 2024
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
JUNO THERAPEUTICS INC0 citations41